DiaMedica Inc.
TSX VENTURE : DMA
OTCQB : DMCAF

DiaMedica Inc.

October 29, 2015 17:00 ET

DiaMedica Appoints Ed Rady as Chief Commercial Advisor

MINNEAPOLIS, MINNESOTA--(Marketwired - Oct. 29, 2015) - DiaMedica Inc. (TSX VENTURE:DMA)(OTCQB:DMCAF) (the "Company"), today announced the appointment of Mr. Ed Rady as the Company's Chief Commercial Advisor. Mr. Rady has over 40 years of wide-ranging pharmaceutical industry experience.

Mr. Rady is the former CEO of Publicis Healthcare Communications Group, the world's largest healthcare communications network in the world. At Publicis, Mr. Rady was charged with the role of organizing, managing, and expanding the worldwide healthcare assets of the Publicis Groupe. He was responsible for 25 diversified businesses in 15 countries and over 3,000 employees. He interacted with virtually all the major pharmaceutical companies and their senior management. Prior to joining Publicis via the B:Com3 acquisition, he held positions as Chief Strategic Officer at Medicus Group and President of Medicus Global Medical Education. Mr. Rady first entered the pharmaceutical communications industry by founding Discovery International, a full-service medical education agency, after leaving a successful 15-year commercial and product management career at Abbott Laboratories. Mr. Rady earned his Bachelor of Science in Biochemistry from the University of Connecticut and an M.B.A. from the Kellogg School of Management at Northwestern University.

"We are delighted to have Ed working with us," said Rick Pauls, DiaMedica's President and CEO. "His experience will help guide DiaMedica though this very important clinical and licensing phase of development."

"I am excited about the opportunity to work with DiaMedica and its team," said Mr. Rady. "DM199 is a unique product with an incredible opportunity to positively impact a number of major diseases, including stroke and kidney disorders."

About DiaMedica

DiaMedica is a clinical stage biopharmaceutical company focused on developing novel treatments for stroke and other vascular diseases. DiaMedica's common shares are listed on the TSX Venture Exchange under the trading symbol "DMA" and on the OTCQB under the trading symbol "DMCAF".

FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. Forward looking statements in this news release include, but are not limited to, the Company's belief of the potential for DM199 to have a positive impact on certain diseases. Factors that could cause actual results to differ materially from such forward-looking information described in detail in the DiaMedica's filings with the Canadian securities regulators, all of which are available on SEDAR (www.sedar.com). Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. DiaMedica undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events, unless required by law. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this press release.

Contact Information

  • DiaMedica Inc.
    Rick Pauls
    President & CEO
    763-270-0603
    info@diamedica.com

    DiaMedica Inc.
    One Carlson Parkway, Suite 124
    Minneapolis, MN